Home | Investors | ASX Announcements | 2020 ASX Announcements 2020 Date Document 31/12/2020 Secondary Trading Notice & Appendix 2A 29/12/2020 Secondary Trading Notice & Appendix 2A 24/12/2020 HepaFat-AI Incorporated into Blackford Analysis 11/12/2020 Secondary Trading Notice & Appendix 2A 09/12/2020 HepaFat-AI gains US FDA clearance 08/12/2020 Trading Halt 08/12/2020 Pause in Trading 27/11/2020 Secondary Trading Notice & Appendix 2A 19/11/2020 Results of Meeting 19/11/2020 Investor Presentation November 2020 26/10/2020 Appendix 4C - quarterly 16/10/2020 Notice of Annual General Meeting/Proxy Form 09/10/2020 Secondary Trading Notice & Appendix 2A 06/10/2020 New Pulmonary Embolism AI Solution Developed 30/09/2020 Appendix 4G and Corporate Governance Statement 30/09/2020 Annual Report to shareholders 10/09/2020 Proposed issue of Securities - RHT 10/09/2020 Execution of Licence Agreement 20/08/2020 Preliminary Final Report 28/07/2020 Appendix 4C - quarterly 26/05/2020 Additional Information on Announcement Dated 25 May 2020 25/05/2020 Resonance Health Files New Provisional Patent 28/04/2020 Appendix 4C - quarterly 06/04/2020 510(k) Application Submission to U.S. FDA 31/03/2020 Market Update 20/03/2020 Secondary Trading Notice & Appendix 2A 19/03/2020 Proposed issue of Securities - RHT 19/03/2020 Controlled Placement Facility 06/03/2020 Secondary Trading Notice & Appendix 2A 21/02/2020 Half Yearly Report and Accounts 04/02/2020 Licencee & Royalty Agreement with 3DR Laboratories 29/01/2020 Appendix 4C - quarterly 13/01/2020 Appendix 3B and Secondary Trading Notice